Check out our most popular compounded medications! Get Started
Phenylpropanolamine HCl 50 mg Oral Tablets are solid, flat-shaped dose forms designed for veterinary use. These tablets are compressed into a convenient oral dosage form, ensuring ease of administration and consistent dosing for the management of these disease states.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Phenylpropanolamine HCl (hydrochloride) is an active pharmaceutical ingredient formulated into 50 mg oral tablets for veterinary use. These solid, flat-shaped tablets are designed to be a convenient mode of administration for animals, ensuring precise dosing and ease of use for pet owners and veterinarians. Phenylpropanolamine is primarily used as a sympathomimetic agent, which means it mimics the effects of the sympathetic nervous system, often leading to vasoconstriction and an increase in blood pressure. In veterinary medicine, it is commonly prescribed for the management of urinary incontinence in dogs, particularly due to its ability to tighten the bladder sphincter muscle.
The efficacy of Phenylpropanolamine in treating urinary incontinence is attributed to its action as an alpha-adrenergic agonist, which helps increase urethral sphincter tone. This action can significantly reduce the occurrence of involuntary urine leakage, improving the quality of life for affected animals. It is important for prescribers to consider the appropriate dosage and monitor for potential side effects, such as hypertension, restlessness, or irritability, which may occur due to the drug's sympathomimetic effects. Additionally, Phenylpropanolamine should be used with caution in animals with pre-existing heart disease, glaucoma, or hyperthyroidism, as it may exacerbate these conditions.
For patients and prescribers considering the use of Phenylpropanolamine HCl 50 mg oral tablets for veterinary applications, it is crucial to have a thorough understanding of the animal's medical history and current health status. A veterinarian should be consulted to determine the suitability of this medication for a specific animal, taking into account any potential drug interactions or contraindications. As compounding pharmacists at Bayview Pharmacy, we are committed to providing high-quality formulations and are available to answer any questions or concerns regarding the use of Phenylpropanolamine HCl in veterinary patients. Please feel free to reach out to us for further information or guidance on this medication.
Phenylpropanolamine HCl (PPA) is a sympathomimetic agent that is used in veterinary medicine primarily for the treatment of urinary incontinence in dogs due to its ability to increase the tone of the urethral sphincter. It may also be used as a decongestant or for its anorectic effects. When considering the use of phenylpropanolamine in any animal, it is crucial to be aware of potential drug interactions that could affect the safety and efficacy of the treatment.
Phenylpropanolamine should be used with caution in animals that are concurrently receiving monoamine oxidase inhibitors (MAOIs) such as selegiline or amitraz, as these can potentiate the effects of sympathomimetics and lead to severe cardiovascular and neurological effects. Similarly, caution is advised when PPA is used with other sympathomimetic drugs, including decongestants and bronchodilators, as the combined effects on the cardiovascular system may be unpredictable and potentially harmful.
Concurrent use of tricyclic antidepressants (TCAs) or selective serotonin reuptake inhibitors (SSRIs) with phenylpropanolamine can also lead to increased blood pressure and other sympathomimetic effects, as these medications can inhibit the reuptake of norepinephrine. It is important to monitor animals closely for signs of hypertension and arrhythmias when these drugs are used together.
Phenylpropanolamine may interact with beta-blockers, leading to a reduction in the effectiveness of the beta-blocker or an increase in PPA's hypertensive effects. The use of PPA with antihypertensive drugs, such as ACE inhibitors or calcium channel blockers, may require dosage adjustments of the antihypertensive medication to maintain blood pressure control.
Animals with pre-existing conditions such as hypertension, hyperthyroidism, glaucoma, or cardiovascular disorders should be closely monitored when treated with phenylpropanolamine, as it may exacerbate these conditions. Additionally, caution is advised when administering PPA to animals with renal insufficiency, as its excretion may be impaired.
It is also important to note that phenylpropanolamine is a prohibited substance in some competitive sports and may result in a positive drug test. Owners of animals competing in such sports should be made aware of this fact to avoid disqualification.
Lastly, over-the-counter cough, cold, and allergy medications, as well as dietary supplements, may contain sympathomimetic agents that could interact with phenylpropanolamine. It is essential to inform the veterinarian of all medications and supplements the animal is receiving before starting treatment with PPA.
For any questions or concerns regarding the use of phenylpropanolamine HCl 50 mg oral tablets for veterinary use, or to report any adverse reactions or unusual symptoms in your pet, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to provide guidance and support to ensure the safe and appropriate use of this medication.
Phenylpropanolamine HCl, commonly referred to as phenylpropanolamine or PPA, is a sympathomimetic agent that is used in veterinary medicine to manage urinary incontinence in dogs, primarily caused by urethral sphincter hypotonus. The active ingredient, phenylpropanolamine, is a synthetic compound that closely resembles the structure of endogenous catecholamines such as epinephrine and norepinephrine. When administered orally, phenylpropanolamine acts by stimulating alpha-adrenergic receptors in the smooth muscle of the urethral sphincter. This stimulation results in increased muscle tone and contraction of the sphincter, thereby reducing the occurrence of urinary incontinence.
The 50 mg oral tablet formulation of Phenylpropanolamine HCl is designed to provide a convenient and precise dosage for veterinary patients. These solid, flat-shaped dose forms are created by compressing the active ingredient, along with excipients that aid in the tablet's stability, dissolution, and absorption, into a compact tablet. The excipients may include binders, fillers, disintegrants, lubricants, and sometimes flavoring agents to make the tablet more palatable for the animal. The tablet is administered orally, typically directly by mouth or mixed with food, and is absorbed through the gastrointestinal tract.
Upon absorption, phenylpropanolamine is distributed throughout the body and reaches the target alpha-adrenergic receptors in the urethral sphincter. The efficacy of phenylpropanolamine in treating urinary incontinence is due to its ability to mimic the action of naturally occurring catecholamines, leading to an increase in urethral sphincter tone. This effect helps to restore the pet's ability to control urination and manage incontinence effectively.
For prescribers and patients considering the use of Phenylpropanolamine HCl 50 mg Oral Tablets for veterinary patients, it is essential to understand the potential side effects and contraindications associated with this medication. Side effects may include restlessness, irritability, increased heart rate, and blood pressure changes. It is also important to consider the animal's medical history and current medications to avoid possible drug interactions. Phenylpropanolamine should be used with caution in animals with pre-existing heart disease, hypertension, or hyperthyroidism. Regular monitoring and follow-up with a veterinarian are recommended to ensure the safety and effectiveness of the treatment.
If you have any questions or require further information about Phenylpropanolamine HCl 50 mg Oral Tablets for veterinary use, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of knowledgeable compounding pharmacists is here to provide guidance and support to ensure the best possible care for your pet.
Phenylpropanolamine HCl (PPA) is primarily known for its use in veterinary medicine to treat urinary incontinence in dogs due to its sympathomimetic effects. Its mechanism of action involves stimulating alpha-adrenergic receptors in the smooth muscle of the urethral sphincter, thereby increasing urethral tone and helping to control urine leakage. However, this medication has a broad pharmacological profile and has been utilized in other contexts as well.
Beyond its application for urinary incontinence, PPA has been used historically in humans as a nasal decongestant and an appetite suppressant. As an appetite suppressant, its stimulation of the central nervous system could lead to decreased appetite. Nevertheless, it is important to note that due to concerns about its safety profile, PPA has been voluntarily withdrawn from the human market in many countries, including the United States, where it is no longer available as an over-the-counter medication for nasal decongestion or weight control due to an increased risk of hemorrhagic stroke in women.
In veterinary practice, apart from its use in treating urinary incontinence, there may be instances where PPA is employed off-label for its sympathomimetic effects, depending on the professional judgment of the prescribing veterinarian. Caution should be exercised in such cases, considering species-specific responses to the drug and the potential for adverse effects.
It is essential for both patients (pet owners) and prescribers to understand the narrow margin of safety for PPA in animals and the need for accurate dosing. Monitoring for side effects such as hypertension, restlessness, irritability, and tachycardia is crucial. Should you have any questions about the uses of Phenylpropanolamine HCl 50 mg Oral Tablets for veterinary use or their off-label applications, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is committed to providing you with the information you need to ensure appropriate treatment for your pets.
Phenylpropanolamine HCl 50 mg Oral Tablets are commonly prescribed in veterinary medicine to treat urinary incontinence in dogs, particularly in spayed female dogs. It works by tightening the bladder sphincter muscle to help control urination.
These tablets should be given orally, usually with food to reduce the chance of gastrointestinal upset. Follow your veterinarian's specific instructions on the dosing schedule for your pet.
No, Phenylpropanolamine is typically for dogs and should only be given to the animal for which it was prescribed. Do not administer this medication to other pets or species without consulting a veterinarian.
Possible side effects can include increased blood pressure, restlessness, irritability, increased heart rate, loss of appetite, or urinary retention. If you notice any severe or worrying symptoms, contact your veterinarian immediately.
Yes, Phenylpropanolamine may interact with other medications. Always inform your veterinarian about any other medications or supplements you are giving your pet to ensure compatibility and avoid potential interactions.
If you miss a dose, give it as soon as you remember. However, if it's almost time for the next dose, skip the missed dose and continue with the regular dosing schedule. Do not double up on doses.
Store the tablets at room temperature, away from excess heat, light, and moisture. Keep them in a secure location where your pet or other animals cannot access them.
No, you should not use human medications as a substitute for veterinary formulas unless specifically directed by a veterinarian, as there are differences in dosing and formulation that could be harmful to your pet.
The safety of Phenylpropanolamine in pregnant or lactating pets has not been well studied. You should use this medication in pregnant or lactating animals only if the potential benefit justifies the potential risk and under the guidance of a veterinarian.
The onset of action for Phenylpropanolamine in dogs varies, but some owners report seeing an improvement in their pet's urinary incontinence within a few days to a week. However, it might take longer to see the full effects, and the treatment's effectiveness should be evaluated by a veterinarian to ensure it is appropriate to continue.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
The conditions listed on this page are indications prescribers have ordered this preparation for. They are not FDA-approved indications, and listing them is not a statement that this preparation is effective for them.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice — discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 tablet by mouth
